Toll Free: 1-888-928-9744

immatics biotechnologies GmbH - Product Pipeline Review - 2014

Published: Mar, 2014 | Pages: 29 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

immatics biotechnologies GmbH - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'immatics biotechnologies GmbH - Product Pipeline Review - 2014', provides an overview of the immatics biotechnologies GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of immatics biotechnologies GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of immatics biotechnologies GmbH including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of immatics biotechnologies GmbH's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the immatics biotechnologies GmbH's pipeline products

Reasons to buy

- Evaluate immatics biotechnologies GmbH's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of immatics biotechnologies GmbH in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the immatics biotechnologies GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of immatics biotechnologies GmbH and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of immatics biotechnologies GmbH
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of immatics biotechnologies GmbH and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
immatics biotechnologies GmbH Snapshot 4
immatics biotechnologies GmbH Overview 4
Key Information 4
Key Facts 4
immatics biotechnologies GmbH - Research and Development Overview 5
Key Therapeutic Areas 5
immatics biotechnologies GmbH - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Out-Licensed Products 9
Out-Licensed Products/Combination Treatment Modalities 10
immatics biotechnologies GmbH - Pipeline Products Glance 11
immatics biotechnologies GmbH - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
immatics biotechnologies GmbH - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
immatics biotechnologies GmbH - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
immatics biotechnologies GmbH - Drug Profiles 15
IMA-901 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
IMA-910 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
IMA-950 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
IMA-962 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
immatics biotechnologies GmbH - Pipeline Analysis 22
immatics biotechnologies GmbH - Pipeline Products by Route of Administration 22
immatics biotechnologies GmbH - Pipeline Products by Molecule Type 23
immatics biotechnologies GmbH - Recent Pipeline Updates 24
immatics biotechnologies GmbH - Company Statement 26
immatics biotechnologies GmbH - Locations And Subsidiaries 27
Head Office 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29
List of Tables
immatics biotechnologies GmbH, Key Information 4
immatics biotechnologies GmbH, Key Facts 4
immatics biotechnologies GmbH - Pipeline by Indication, 2014 6
immatics biotechnologies GmbH - Pipeline by Stage of Development, 2014 7
immatics biotechnologies GmbH - Monotherapy Products in Pipeline, 2014 8
immatics biotechnologies GmbH - Out-Licensed Products in Pipeline, 2014 9
immatics biotechnologies GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2014 10
immatics biotechnologies GmbH - Phase III, 2014 11
immatics biotechnologies GmbH - Phase II, 2014 12
immatics biotechnologies GmbH - Phase I, 2014 13
immatics biotechnologies GmbH - Preclinical, 2014 14
immatics biotechnologies GmbH - Pipeline by Route of Administration, 2014 22
immatics biotechnologies GmbH - Pipeline by Molecule Type, 2014 23
immatics biotechnologies GmbH - Recent Pipeline Updates, 2014 24 



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify